Présentation de l'entreprise
Mainz Biomed N.V. is a specialized entity within the healthcare sector, specifically operating in the diagnostics and research industry by developing and commercializing in-vitro diagnostic (IVD) tests designed for the early detection of cancer across the United States and European markets. The company's core product portfolio includes ColoAlert, a molecular genetic stool test focused on colorectal cancer, alongside PancAlert, which serves as a stool-based screening solution for pancreatic cancer detection. As of the latest reporting period, the firm maintains a market capitalization of $5.95M and generates annual revenue totaling $1.07M, while its employee count is not disclosed in available public filings. These valuation metrics indicate that Mainz Biomed N.V. functions as a micro-cap enterprise, suggesting a nascent stage of commercialization where revenue generation is currently constrained by the early adoption phase of its diagnostic technologies rather than established mass-market sales volumes.
Santé financière
The financial statements for Mainz Biomed N.V. reflect a significant disparity between its top-line performance and bottom-line profitability, with trailing twelve-month (TTM) revenue recorded at $1.07M against a net income loss of $16,210,718. This substantial gap between revenue and net income reveals a highly aggressive cost structure or one-time expenses that are not fully covered by current operational revenues, resulting in an EBITDA figure of $-12,349,595. Furthermore, the company's free cash flow stands at $-9,546,315, which indicates a negative cash conversion cycle where operating activities and capital expenditures are consuming liquid assets faster than they are being replenished. The margin analysis highlights a gross margin of 81.1%, demonstrating efficient production costs for its diagnostic kits, yet this is overshadowed by an operating margin of -621.8% and a profit margin of 0.0%, signaling that general and administrative expenses are disproportionately high relative to sales. Liquidity is further constrained by a cash balance of $889,091 sitting against total debt obligations of $2.57M, resulting in a debt-to-equity ratio of 400.80 that characterizes the balance sheet as highly leveraged and potentially vulnerable to refinancing risks. Short-term liquidity pressure is exacerbated by a current ratio of 0.50, meaning current liabilities exceed current assets, which limits the company's ability to meet immediate obligations without external financing. Finally, the return on equity is reported at -484.8% and the return on assets at -87.3%, metrics that reveal that management is currently destroying shareholder value and failing to generate positive returns on the capital base deployed in the business.
Évaluation de la valorisation
Valuation multiples for Mainz Biomed N.V. present a complex picture due to the absence of profitable earnings, as evidenced by the N/A status for both the P/E Ratio (TTM) and the Forward P/E, which implies that traditional earnings-based valuation models are currently inapplicable or that the market is pricing in a hypothetical future earnings trajectory that has not yet materialized. Alternative valuation metrics provide a clearer picture of the asset's pricing relative to its tangible book value, with a price-to-book ratio of 0.77 indicating that the market values the company at a discount to its net asset value, though this may reflect the risk associated with its negative earnings. The price-to-sales ratio stands at 5.55, while the EV/EBITDA is calculated at -0.50, suggesting that investors are paying a premium relative to sales volume given the company's lack of profitability. Price volatility is evident in the stock's trading range, which spans from a 52-week low of $0.40 to a 52-week high of $4.43, and without a specific current price to calculate the exact percentage deviation, the range itself underscores the speculative nature of the investment. Additionally, the Beta value is listed as N/A, meaning that the stock's historical volatility relative to the broader market index cannot be quantified from the provided data, leaving the risk profile dependent on individual market sentiment rather than historical correlation metrics.
Growth & Income
The company's revenue growth trajectory is robust, showing a year-over-year increase of 86.9%, whereas earnings growth is listed as N/A due to the consistent net losses, implying that top-line expansion is occurring without a corresponding improvement in profitability. Since Mainz Biomed N.V. does not pay dividends, indicated by a dividend yield of N/A and a payout ratio of 0.0%, the firm does not distribute cash to shareholders, and the payout ratio is technically non-existent as there are no earnings to distribute. Instead of paying dividends, the company is forced to reinvest its limited resources or seek external capital to fund operations, as the negative free cash flow precludes any sustainable dividend policy. The overall growth and income profile is defined by rapid revenue expansion coupled with significant financial distress, where the company prioritizes market penetration and product development over income generation or capital preservation.